Brief: Percheron Therapeutics Says Vanderbilt Health To Conduct Clinical Trial Of Hmbd-002 In Acute Myeloid Leukaemia
28/08/2026 02:32
BRIEF-Percheron Therapeutics Says Vanderbilt Health To Conduct Clinical Trial Of Hmbd-002 In Acute Myeloid Leukaemia Aug 28 (Reuters) - Percheron Therapeutics Ltd PER.AX:
VANDERBILT HEALTH TO CONDUCT CLINICAL TRIAL OF HMBD-002 IN ACUTE MYELOID LEUKAEMIA
Further company coverage: PER.AX
((reuters.briefs@thomsonreuters.com;))
Recent news on Percheron Therapeutics
See all newsBrief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Brief: Percheron Therapeutics Receives Firm Commitments For A$2.3 Million Institutional Placement
Brief: Percheron Therapeutics Appoints Ambrosini as Interim Board Member During CEO Transition Period
Brief: Percheron Therapeutics Says Vanderbilt Health To Conduct Clinical Trial Of Hmbd-002 In Acute Myeloid Leukaemia
Brief: Percheron Therapeutics Says James Garner To Step Down As CEO And Managing Director